Evolutionary Pressure against MHC Class II Binding Cancer Mutations
暂无分享,去创建一个
Hannah Carter | Rany M. Salem | Maurizio Zanetti | W. Thompson | H. Carter | R. Salem | M. Zanetti | J. Font-Burgada | Rachel Marty Pyke | Wesley Kurt Thompson | Joan Font-Burgada | Rachel Marty Pyke | Joan Font-Burgada
[1] J. Voorberg,et al. Analysis of the HLA‐DR peptidome from human dendritic cells reveals high affinity repertoires and nonconventional pathways of peptide generation , 2017, Journal of leukocyte biology.
[2] James Robinson,et al. The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..
[3] B. Bogen,et al. How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? , 2014, Front. Immunol..
[4] O. Lund,et al. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ , 2013, Immunogenetics.
[5] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[6] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[7] Hao Shen,et al. Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.
[8] R. Yamada,et al. HLA‐HD: An accurate HLA typing algorithm for next‐generation sequencing data , 2017, Human mutation.
[9] M. Nielsen,et al. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.
[10] Angela Bachi,et al. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. , 2003, Blood.
[11] S. Wood. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models , 2011 .
[12] PATHOGEN RESISTANCE AND GENETIC VARIATION AT MHC LOCI , 2002, Evolution; international journal of organic evolution.
[13] Juan R. Cubillos-Ruiz,et al. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis , 2015, Cell.
[14] M. Bevan,et al. Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.
[15] Sebastian Bonhoeffer,et al. Virus evolution: The importance of being erroneous , 2002, Nature.
[16] María Martín,et al. UniProt: A hub for protein information , 2015 .
[17] The Uniprot Consortium,et al. UniProt: a hub for protein information , 2014, Nucleic Acids Res..
[18] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[19] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[20] H. Friess,et al. Loss of heterozygosity in the HLA class I region in human pancreatic cancer. , 2004, Tissue antigens.
[21] J. Yewdell,et al. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. , 2005, Annual review of immunology.
[22] E. Kirkness,et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA , 2017, Proceedings of the National Academy of Sciences.
[23] M. Berger,et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.
[24] S. Elledge,et al. Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.
[25] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[26] Alessandro Vullo,et al. Ensembl 2017 , 2016, Nucleic Acids Res..
[27] Frank Noé,et al. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation , 2017, Front. Immunol..
[28] T. Ideker,et al. MHC-I Genotype Restricts the Oncogenic Mutational Landscape , 2017, Cell.
[29] I. Messaoudi,et al. Direct Link Between mhc Polymorphism, T Cell Avidity, and Diversity in Immune Defense , 2002, Science.
[30] M. Croft,et al. Functional cooperation between T helper cell determinants. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[31] Erik Sahai,et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.
[32] M. Zanetti. Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics , 2015, The Journal of Immunology.
[33] Lincoln D. Stein,et al. Quantifying immune-based counterselection of somatic mutations , 2017, bioRxiv.
[34] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.
[35] Mark J. Smyth,et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity , 2012, The Journal of experimental medicine.
[36] Rong Wang,et al. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. , 2001, Trends in immunology.
[37] Urs Christen,et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.
[38] Jérôme Galon,et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.
[39] Benjamin Schubert,et al. OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..
[40] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[41] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[42] M. Nowak,et al. Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.
[43] Sean C. Bendall,et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy , 2017, Cell.
[44] Morten Nielsen,et al. An automated benchmarking platform for MHC class II binding prediction methods , 2018, Bioinform..
[45] M. Bevan,et al. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection , 2004, Nature Immunology.
[46] Steven J. M. Jones,et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.
[47] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[48] Yu Shyr,et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.
[49] E. Unanue,et al. Variations in MHC Class II Antigen Processing and Presentation in Health and Disease. , 2016, Annual review of immunology.
[50] J. Goedert,et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.
[51] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[52] K. Cibulskis,et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.
[53] D. Cassell,et al. Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes a , 1988, Annals of the New York Academy of Sciences.
[54] N. Mitchison,et al. The carrier effect in the secondary response to hapten‐protein conjugates. I. Measurement of the effect with transferred cells and objections to the local environment hypothesis , 1971, European journal of immunology.
[55] Jianhong Cao,et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.
[56] S. Xiong,et al. Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus , 2003, European journal of immunology.
[57] R. Zinkernagel,et al. Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex , 1975, Nature.
[58] Angela E. Leek,et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.
[59] E. Appella,et al. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. , 2000, Cancer research.
[60] K. Willert,et al. Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells , 2017, Science Signaling.
[61] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[62] W. Thompson,et al. Evolutionary Pressure against MHC Class II Binding Cancer Mutations , 2018, Cell.
[63] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.
[64] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[65] Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. , 2015, Journal of immunological methods.
[66] Andrew R. Jones,et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..
[67] Trey Ideker,et al. Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. , 2017, Cancer discovery.